Source comparison
MOTS-c vs Metformin vs AICAR: Research Tool Comparison
| Compound | AMPK Activation Mechanism | Primary Research Use | Mitochondrial Specificity | Dose-Limiting Toxicity | Our Assessment for AMPK Research ||—|—|—|—|—|| MOTS-c | Mitochondrial stress → AMP:ATP ratio increase → AMPK phosphorylation | Metabolic flexib
This comparison does not assign a generated winner or score.
- | Compound | AMPK Activation Mechanism | Primary Research Use | Mitochondrial Specificity | Dose-Limiting Toxicity | Our Assessment for AMPK Research ||—|—|—|—|—|| MOTS-c | Mitochondrial stress → AMP:ATP ratio increase → AMPK phosphorylation | Metabolic flexibility, insulin resistance, mitochondrial-nuclear crosstalk | High. Mitochondrial-encoded peptide | Minimal at research doses (5–15 mg/kg in mice) | Best tool for studying retrograde mitochondrial signaling; models physiological AMPK activation more closely than pharmacological agonists || Metformin | Complex I inhibition → reduced ATP synthesis → AMP accumulation | Type 2 diabetes models, cancer metabolism, caloric restriction mimetics | Moderate. Affects mitochondria but also cytoplasmic pathways | Lactic acidosis at high doses; GI distress in humans | Useful for direct AMPK activation but lacks mitochondrial signaling specificity || AICAR | AMP mimetic. Binds AMPK gamma subunit directly | Exercise mimetic studies, cardiac ischem